Live Analyst Rating Changes 1656 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Mathew Blackman
TD
Mathew Blackman
TD Cowen
Wall Street Analyst
★★☆☆☆
#2002
on 13Foresight · ranked by our own returns
65%
Success Rate
-0.9%
Average Return
11 of 17 calls profitable · -369.3% vs benchmark
📈 Across the calls we could measure, roughly 65% of Mathew Blackman's ratings turned a profit when each position was held for 1 year — averaging -0.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

24 Buy 14 Hold 0 Sell
Mathew's Stock Coverage 18 ratings · 2026-06-22
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
KIDS
OrthoPediatrics
 Jun 12, 2026 BUY Strong Buy
+59.0% avg upside
10 analysts
$23.00
21.98% Upside
 ·
OFIX
Orthofix Medical
 May 21, 2026 HOLD Strong Buy
+207.1% avg upside
15 analysts
$12.00
27.01% Upside
 ·
SIBN
SI-Bone
 May 12, 2026 BUY Strong Buy
+60.4% avg upside
18 analysts
$18.00
13.59% Upside
 +1.9%
TNDM
Tandem Diabetes Care
 May 08, 2026 BUY Strong Buy
+116.0% avg upside
29 analysts
$28.00
83.04% Upside
 -3.9%
GMED
Globus Medical
 May 08, 2026 BUY Strong Buy
+21.0% avg upside
24 analysts
$115.00
45.24% Upside
 +1.6%
ATEC
Alphatec Holdings
 May 06, 2026 BUY Strong Buy
+112.8% avg upside
22 analysts
$11.00
24.81% Upside
 +15.7%
SYK
Stryker
 May 01, 2026 HOLD Strong Buy
+24.0% avg upside
36 analysts
$355.00
15.28% Upside
 +2.2%
ZBH
Zimmer Biomet Holdings
 Apr 28, 2026 BUY Buy
+27.6% avg upside
37 analysts
$109.00
23.89% Upside
 +7.2%
ISRG
Intuitive Surgical
 Apr 22, 2026 BUY Strong Buy
+29.4% avg upside
36 analysts
$585.00
43.79% Upside
 -15.9%
BBNX
Beta Bionics, Inc.
 Apr 21, 2026 HOLD Strong Buy
+51.9% avg upside
13 analysts
$16.00
15.19% Upside
 +18.4%
PODD
Insulet
 Feb 19, 2026 HOLD Strong Buy
+79.1% avg upside
32 analysts
$294.00
101.66% Upside
 -41.5%
CLPT
ClearPoint Neuro
 May 14, 2025 BUY Strong Buy
+13.7% avg upside
7 analysts
$25.00
40.77% Upside
 +2.7%
INGN
Inogen
 May 08, 2025 HOLD Buy
+284.8% avg upside
7 analysts
$7.00
9.17% Upside
 +10.5%
DXCM
Dexcom
 May 02, 2025 BUY Strong Buy
+38.6% avg upside
32 analysts
$100.00
37.93% Upside
 -24.8%
PEN
Penumbra
 Apr 24, 2025 BUY Buy
+4.4% avg upside
23 analysts
$318.00
0.21% Upside
 +10.6%
SENS
Senseonics Holdings
 Mar 04, 2025 BUY Buy
+124.7% avg upside
13 analysts
$50.00
641.74% Upside
 -51.1%
AHCO
AdaptHealth
 Feb 27, 2025 HOLD Strong Buy
+48.1% avg upside
12 analysts
$11.00
13.89% Upside
 -17.5%
CERS
Cerus
 Jan 13, 2025 BUY Strong Buy
+99.1% avg upside
10 analysts
$3.00
11.02% Upside
 +50.9%
🔒 13 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Mathew Blackman — Frequently Asked Questions
How accurate are Mathew Blackman's stock ratings?
Based on the calls 13Foresight could measure, about 65% of Mathew's ratings were profitable over a one-year hold, with an average return of -0.7% per rating, or -369.2% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Mathew ranked on 13Foresight?
Mathew Blackman is currently ranked #2002 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Mathew cover?
Mathew most recently has ratings on KIDS, OFIX, SIBN, TNDM, GMED, ATEC, SYK, ZBH, ISRG, BBNX, PODD, CLPT and 6 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.